Researchers find way to treat lung cancer and associated muscle wasting at the same time | Newsroom PORTLAND, Ore. – Researchers at Oregon State University have developed a technique for simultaneously treating lung cancer and a serious muscle-wasting condition that often accompanies it. The study,…

Oregon State University researchers have made a compelling dual-target discovery. They have developed a single therapy that simultaneously targets lung cancer and cancer cachexia. #lungcancer
news.oregonstate.edu/news/researc...

EGFR Biology and Treatment Selection Beyond PD-L1 in EGFR-Mutated NSCLC | CancerNetwork In this segment, Alexander Spira, MD, PhD, engages Natalie Vokes, MD, in a discussion on the distinct biology of EGFR-mutated non–small cell lung cancer and how it informs treatment decisions in the…

EGFR-mutated NSCLC is not just another subtype of lung cancer — it is a distinct molecular entity that demands a fundamentally different treatment strategy. #lungcancer
www.cancernetwork.com/view/egfr-bi...

New AI tool predicts whether aggressive small cell lung cancer will respond to treatment Results of a new study conclude that a pathology tool powered by artificial intelligence can predict whether a patient with extensive-stage small cell lung cancer will respond to platinum-based…

Researchers at Roswell Park Comprehensive Cancer Center and Winship Cancer Institute of Emory University have developed an AI-powered tool that can predict treatment response in extensive-stage small cell lung cancer before a single dose of chemotherapy is given. #lungcancer

Mount Sinai Study Finds Lung Cancer Surgery Safe for Many Patients Over 80 Left to right: Emanuela Taioli, MD, PhD; Raja M. Flores,MD; Claudia Henschke, PhD, MD; and David F. Yankelevitz, MD.

New research is challenging the idea of how old is too old for surgery in early-stage lung cancer. #lungcancer
www.mountsinai.org/about/newsro...

Congrats to the researchers at the ALCMI consortium member, Mass General Brigham Cancer Institute. They have shown that pralsetinib can extend median overall survival for advanced RET fusion-positive NSCLC from roughly 4–11 months to 44 months. #lungcancer
www.massgeneralbrigham.org/en/about/new...

Novel Small Molecule Earns FDA Fast Track Designation in ALK+ NSCLC | CancerNetwork Investigators are currently evaluating treatment with TRI-611 among patients with ALK-positive non–small cell lung cancer in a phase 1/2 trial.

Congrats to TRIANA Biomedicines! The company has earned FDA Fast Track designation for TRI-611, a first-in-class molecular glue degrader targeting ALK fusion proteins in ALK-positive non-small cell lung cancer. #lungcancer
www.cancernetwork.com/view/novel-s...

Humanetics Corporation Announces Investigator-Initiated Phase 2 Trial in Patients with Non-Small Cell Lung Cancer and Underlying Interstitial Lung Disease MINNEAPOLIS, March 31, 2026--Investigator-initiated at a leading cancer center will provide explore BIO 300's potential.

New trial alert! Memorial Sloan Kettering Cancer Center has launched a new investigator-initiated Phase 2 trial evaluating BIO 300 Oral Suspension in patients with non-small cell lung cancer and concomitant interstitial lung disease. #lungcancer
finance.yahoo.com/sectors/heal...

Significant Incidental Findings and Diagnosis of Extrapulmonary Cancer This cohort study examines the association between significant incidental findings on lung cancer screening in the National Lung Screening Trial and the diagnosis of an extrapulmonary cancer within 1…

A new study found that incidental findings flagged during low-dose CT screening could be signs of other non-lung, undiagnosed cancers. #lungcancer
jamanetwork.com/journals/jam...

How Risk Benefit Profiles Aid in Treatment Selection in EGFR+ NSCLC | OncLive Christine Lovly, MD, PhD, and Matthew Lee, MD, discuss how data help shape first-line treatment decisions in EGFR-mutated non–small cell lung cancer.

Dr. Lovly and Dr. Lee examined how risk-benefit profiles should drive frontline treatment selection, weighing efficacy, toxicity, and patient-specific factors when choosing between osimertinib monotherapy and combination approaches. #lungcancer

Dr Girard on Updated Data From the PALOMA-2 Trial in EGFR-Mutant NSCLC | OncLive Nicolas Girard, MD, PhD, discusses updated data from the phase 2 PALOMA-2 trial (NCT05498428) that were presented at the 2026 European Lung Cancer Congress.

Updated data from the phase 2 PALOMA-2 trial point to a meaningful advance in first-line treatment for patients with EGFR-mutated metastatic NSCLC. #lungcancer
www.onclive.com/view/dr-gira...

Researchers Discover That Lung Cells Have Different Aging Rates In this study, the researchers obtained data characterizing cells from sixty different samples of human lungs. The samples came from donors who ranged from 11 to 80 years old. The data included single-cell RNA sequencing, which identifies genes that are active in a cell at one point in time.

Fascinating! Researchers have identified that lung cells age at different rates, with implications for lung cancer risk and targeted therapies. #lungcancer
www.labroots.com/trending/cel...

TNIK overexpression is sufficient for chemoradiation resistance in limited-stage small cell lung cancer Abstract. Small cell lung cancer (SCLC) is characterized by early metastasis, intrinsic chemoradiation resistance and tumor recurrence. Besides the lack of potentially targetable oncogenic drivers,…

New research into treatment resistance! Researchers at Johns Hopkins Medicine have identified a promising new therapeutic target that could overcome one of the most stubborn challenges in small cell lung cancer treatment. #lungcancer
aacrjournals.org/mct/article-...

Common p53 genetic mutation reveals Achilles' heel in lung cancer A team of researchers at VCU Massey Comprehensive Cancer Center has identified a new pathway through which mutations in the tumor suppressor p53 gene—found very frequently in human tumors—hijack DNA…

Researchers at VCU Massey Comprehensive Cancer Center have uncovered a critical vulnerability in p53-mutant lung tumors, and it could reshape how we treat a majority of patients. #lungcancer
medicalxpress.com/news/2026-03...

bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer Diagnostic SAN ANTONIO, March 10, 2026--bioAffinity Technologies launches 2,000-patient longitudinal study for its CyPath Lung noninvasive diagnostic for lung cancer.

We'll be keeping tabs on this one. bioAffinity Technologies has launched a landmark 2,000-patient longitudinal study that could redefine how we approach early lung cancer detection. #lungcancer
finance.yahoo.com/news/bioaffi...

Methylation signatures distinguish non small cell lung cancer subtypes and associated with survival in smokers with lung squamous cell carcinoma AbstractIntroduction. Lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) are the two major histologic subtypes of non-small cell lung cance

Wow! Researchers at Dartmouth College and Baylor University have identified a DNA methylation signature that distinguishes the two major subtypes of non-small cell lung cancer and predicts early survival in smokers with lung squamous cell carcinoma. #lungcancer

Study adds evidence linking Medicaid expansion to earlier lung cancer diagnosis and improved survival | Managed Healthcare Executive A nationwide analysis of adults newly diagnosed with non-small cell lung cancer found that Medicaid expansion was associated with earlier-stage diagnosis, more timely initiation of…

Medicaid expansion under the Affordable Care Act is saving lives, and a landmark study of more than 514,000 NSCLC patients now quantifies exactly how much. #lungcancer
www.managedhealthcareexecutive.com/view/study-a...

Outcomes of Early Versus Delayed Initiation of Immunotherapy in Patients With Extensive-Stage Small Cell Lung Cancer BACKGROUND: Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive form of lung cancer associated with poor prognosis, and treatment goals are focused on prolonging survival and symptom…

Researchers at Novant Health have found that delaying immunotherapy initiation in extensive-stage small cell lung cancer does not compromise survival outcomes, offering a clinically meaningful insight for patients who require emergent hospitalization at diagnosis. #lungcancer

Lung Cancer Metastasis Driven by ATF4 Stress Response Pathway Lung tumors often grow more slowly but are more likely to spread to other organs, a pattern linked to increased activity of the protein ATF4.

Researchers at the University of Gothenburg have uncovered a key molecular driver of lung cancer metastasis in older patients. #lungcancer
www.insideprecisionmedicine.com/topics/oncol...

Severe COVID or flu may raise lung cancer risk years later A severe case of COVID-19 or influenza could increase the risk of lung cancer later on, according to new research. Scientists discovered that serious viral infections can alter immune cells in the…

Whoa! This is big. Researchers at UVA Health have identified a direct link between severe respiratory viral infections and increased lung cancer risk. #lungcancer
www.sciencedaily.com/releases/202...

New Device May Deliver Faster Lung Cancer Results and Diagnoses | CURE This device detects and characterizes lesions on low-dose CT scans, helping patients with cancer get faster, tailored care and avoid unnecessary procedures.

Median Technologies' Eyonis LCS has received FDA 510(k) clearance as the first AI-based device for both detecting and diagnosing lung cancer in low-dose CT scans. #lungcancer
www.curetoday.com/view/new-dev...

ISL1: A Novel Neuroendocrine Subtype in Small Cell Lung Cancer Predicts Durable Response to Lurbinectedin Abstract. Small cell lung cancer (SCLC) is a recalcitrant thoracic malignancy known for acquired chemoresistance, early metastatic spread, and poor overall survival. Lurbinectedin, a DNA minor groove…

Congratulations to Misty Shields and colleagues at the Indiana University School of Medicine and Moffitt Cancer Center! #lungcancer
aacrjournals.org/mct/article-...

Client Challenge Please enable JavaScript to proceed.

Must-read insights from our good friend Dr. Jorge Nieva from USC Norris Comprehensive Cancer Center! #lungcancer
www.hmpgloballearningnetwork.com/site/jcp/int...

Proximity to nuclear power plants associated with increased cancer mortality | Harvard T.H. Chan School of Public Health U.S. counties located closer to operational nuclear power plants have higher rates of cancer mortality than those located farther away, according to a new Harvard Chan School study.

A comprehensive national study led by Harvard T.H. Chan School of Public Health found that U.S. counties located closer to operational nuclear power plants experience higher cancer mortality rates than those farther away. #lungcancer
hsph.harvard.edu/news/proximi...

Cancer Stress Protein Helps Tumors Hide From Immunity /PRNewswire/ -- A protein made by stressed cancer cells helps lung and pancreatic tumors evade the immune system, a new study shows. Led by researchers from...

Congrats to ALCMI consortium member NYU Langone Health! Researchers there have discovered that lipocalin 2 (LCN2) enables lung and pancreatic tumors to evade immune attack by manipulating immune cells in the tumor microenvironment. #lungcancer

Inhaled microplastics linked to lung cancer, asthma and fibrosis - AirQualityNews Microplastics in the air are infiltrating human lungs, triggering oxidative stress, inflammation and cellular damage that may contribute to a range of serious respiratory diseases, a comprehensive…

Microplastics may be emerging as a serious danger to lung health. #lungcancer
airqualitynews.com/headlines/in...

Mayo Clinic study identifies mechanism behind immunotherapy resistance in lung cancer The study, published in Cancer Immunology Research, focuses on regulatory T cells, immune cells that normally keep the immune system from becoming overactive.

Whoa! Mayo Clinic researchers led by Henrique Borges da Silva, Ph.D., have uncovered how lung tumors exploit regulatory T cells via P2RX7 to evade immunotherapy. #lungcancer
newsnetwork.mayoclinic.org/discussion/m...

Hypofractionation is ‘Excellent Tool’ in Radiotherapy for Lung Cancer | CancerNetwork Pranshu Mohindra, MD, outlined considerations for optimizing the use of hypofractionated radiation for patients with lung cancer.

Pranshu Mohindra, MD, MMM, from University Hospitals Cleveland Medical Center Inc., presents a compelling case for expanding the use of hypofractionated radiotherapy in lung cancer treatment. #lungcancer
www.cancernetwork.com/view/hypofra...

Congratulations to Johnson & Johnson! The FDA has approved RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy with monthly subcutaneous dosing for first-line EGFR-mutated advanced NSCLC. #lungcancer
www.jnj.com/media-center...

Atezolizumab Plus Concurrent Chemoradiation Fails to Improve Survival in LS-SCLC | OncLive Data from the phase 3 LU005 trial found no OS benefit and high immune-related toxicity with concurrent/adjuvant atezolizumab and chemoradiation in LS-SCLC.

The NRG ONCOLOGY/Alliance Healthcare LU005 trial shows that concurrent and adjuvant atezolizumab added to chemoradiation does not improve overall survival in limited-stage small cell lung cancer, as published in the Journal of Clinical Oncology. #lungcancer

Epithelial Injury Biomarkers Linked to Lung Abnormalities After COVID-19 Injury and scarring markers are seen in association with RLA on follow-up CT following recovery from COVID-19.

New news on COVID-19 and lung cancer. Imperial College London researchers have uncovered epithelial injury biomarkers that predict residual lung abnormalities in COVID-19 survivors, as detailed in a new eBioMedicine study led by Iain Stewart, Ph.D. #lungcancer